Lake Street Maintains Buy on Cellebrite DI, Lowers Price Target to $15
Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $21 to $15.
Read original at benzingaStocks · News reference
Cellebrite DI Sees Q3 Sales $145.000M-$148.000M vs $150.298M Est
Cellebrite DI (NASDAQ:CLBT) sees Q3 sales of $145.000 million-$148.000 million vs $150.298 million analyst estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 11:23 AM
- Checked
- Aug 13, 2026, 11:23 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $16
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and lowers the price target from $20 to $16.
Read original at benzingaDA Davidson Maintains Buy on Cellebrite DI, Lowers Price Target to $15
DA Davidson analyst Rudy Kessinger maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $22 to $15.
Read original at benzingaNeedham Maintains Buy on Cellebrite DI, Lowers Price Target to $12.5
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $15 to $12.5.
Read original at benzinga